<DOC>
	<DOCNO>NCT02056756</DOCNO>
	<brief_summary>Open-label phase Ib/II , multicenter , international non-comparative trial . This study design determine safety efficacy novel salvage regimen ( CBd ) follow carfilzomib maintenance patient relapse refractory multiple myeloma . Patients evaluate scheduled visit 4 study period : pretreatment , treatment , maintenance long-term follow-up ( LTFU ) .</brief_summary>
	<brief_title>Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma ( MM ) one common hematological disease besides option allogeneic stem cell transplantation remain incurable . Although autologous stem cell transplantation new compound bortezomib , thalidomide lenalidomide implement , treatment alternative patient relapse refractory therapy urgently need . In addition , patient often compromise toxicity prior treatment allow use active drug due neurotoxicity bortezomib give . However , contrast bortezomib investigative drug carfilzomib block , proteasome irreversibly show minimal activity off-target enzyme lead sustained proteasome inhibition distinctive toxicity profile [ 1-3 ] . Carfilzomib promise single agent activity phase II trial heavily pre-treated MM patient ( overall response rate 24 % [ 4 ] ) . Another drug substantial activity lymphoid malignancy bendamustine , recently find superior chlorambucil chronic lymphocytic leukemia ( CLL ) [ 5 ] well Non-Hodgkin 's lymphoma ( NHL ) [ 6 ] . In multiple myeloma , bendamustine combine prednisone ( BP ) superior melphalan prednisone ( MP ) far complete remission rate , time treatment failure life quality [ 7 ] . Therefore , bendamustine , alkylating agent , recently license Europe NHL , CLL MM . The addition bendamustine able overcome bortezomib resistance institutional treatment algorithm [ 8 ] line observation bortezomib enhance clinical activity alkylator melphalan conventional dos well high dose set [ 9-10 ] . Thus , appear rationale combine drug order obtain clinical synergistic activity relapse refractory MM patient . STUDY OBJECTIVES Primary objective : - The dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) carfilzomib , bendamustine dexamethasone ( CBd ) association ( phase Ib ) . - Determine rate good partial response ( VGPR ) CBd association : VGPR rate 20 % ( p0 ) consider promising ( H0 ) 40 % ( p1 ) interesting ( phase II ) . Secondary objective : - Determine overall response rate ( ORR ) completion CBd - Determine progression-free survival ( PFS ) completion CBd - Determine time point best response - Determine time progression ( TTP ) - Determine disease free survival ( DFS ) - Determine duration response ( DOR ) - Determine time next therapy ( TTNT ) - Determine overall survival ( OS ) - Determine whether tumor response survival might significantly change particular subgroup patient define prognostic factor ( B2- microglobulin , C-reactive protein , cytogenetic abnormality determine FISH ) STUDY POPULATION Relapsed refractory multiple myeloma failure two treatment regimen . Up 68 patient enrol different center . INCLUSION CRITERIA - Patient ≥ 18 year old . - Patient , investigator ( ) opinion , willing able comply protocol requirement . - Patient give voluntary write informed consent performance study-related procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . - Female patient either post-menopausal surgically sterilize commits continue abstinence heterosexual intercourse duration study willing use two method birth control , one highly effective method one additional effective method time , least 4 week start carfilzomib bendamustine therapy , carfilzomib bendamustine therapy least 4 week stop carfilzomib bendamustine therapy . Highly effective method hormonal contraceptive ( birth control pill , injection , implant ) , intrauterine device , tubal ligation partner 's vasectomy . Additional effective method condom , diaphragm , cervical cap . Women child bear potential must two negative pregnancy test ( sensitivity least 50 mIU/mL ) prior start carfilzomib bendamustine therapy . The first pregnancy test must perform 10 - 14 day second within 24 hour start carfilzomib bendamustine therapy . Pregnancy test first 4 week study therapy must perform weekly thereafter every 4 week menstrual cycle regular every 2 week menstrual cycle irregular . - Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) duration study 6 month stop study therapy . - Patient relapse or/and refractory multiple myeloma failure two treatment regimen ( previous bortezomib allow ) . - Patient measurable disease , define follow : quantifiable serum monoclonal protein ( M-protein ) value ( generally , necessarily , ≥ 0.5 g/dL M-protein ) , applicable , urine light-chain excretion &gt; 200 mg/24 hour . For patient oligo- non-secretory MM , require measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CT-Scan ) abnormal free light chain ratio ( n.v. : 0.26-1.65 ) . We anticipate less 10 % patient admit study oligo- non-secretory MM free light chain order maximize interpretation benefit result . - Patient Karnofsky performance status ≥60 % . - Patient life expectancy &gt; 6 month . - Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 , study drug administration ) : - Platelet count ≥70 x 109/L ( ≥50 x 109 /L myeloma involvement bone marrow &gt; 50 % ) within 14 day prior drug administration ) . - Absolute neutrophil count ( ANC ) ≥ 1 x 109/L without use growth factor . - Corrected serum calcium ≤14 mg/dL ( 3.5 mmol/L ) . - Alanine transaminase ( ALT ) : ≤ 3 x ULN . - Total bilirubin : ≤ 2 x ULN . - Calculated measured creatinine clearance ≥ 15 mL/min ( , alternative serum creatinine &lt; 2 mg/dL ) . - LVEF ≥ 40 % . 2-D transthoracic echocardiogram ( ECHO ) prefer method evaluation . Multigated Acquisition Scan ( MUGA ) acceptable ECHO available ( applicable Germany ) . EXCLUSION CRITERIA - Pregnant lactating female - Patient active infectious hepatitis type B C HIV . - Patients active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention . - Peripheral neuropathy ( PN ) &gt; CTCAE grade 2 ≥ grade 2 painful PN ( difference exclusion patient Grade 2 painful PN ) . - Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) - Known history intolerability high dose dexamethasone - Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation anti-platelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . - Subject pleural effusion require thoracentesis ascites require paracentesis within 14 day prior baseline ; - Patient clinically significant illness would , investigator 's opinion , increase patient 's risk toxicity . - Patient prior malignancy within last 5 year ( except basal squamous cell carcinoma skin , situ cancer cervix breast , localized prostate cancer Gleason score &lt; 7 stable PSA ) . The pre-treatment period include screen visit , perform study entry . After provide write informed consent participate study , patient evaluate study eligibility . The screening period include availability inclusion criterion describe . The treatment period include administration CBd 8 course . In order ass toxicity treatment , patient attend study center visit schedule carfilzomib administration . The response assess cycle . The maintenance period start end 8th course , patient achieve least Stable Disease ( SD ) , stop progression intolerance . Patients attend study center visit schedule carfilzomib administration . The response assess cycle . The median expect duration maintenance treatment approximately 1 year . The LTFU period start development confirm progressive disease ( PD ) . All patient follow survival LTFU period every 3 month via telephone office visit . STUDY TREATMENT Patients start savage treatment CBd , soon screen visit pre-treatment period terminate . Patients receive 8 CBd cycle . PHASE I In phase I part study , follow dose level carfilzomib bendamustine study constant dose dexamethasone : Level -2 Carfilzomib = 20 mg/m2 IV daily day 1 , 2 cycle 1 follow 27 mg/m2 day 8 , 9 , 15 , 16 cycle 1 , subsequent dose 27 mg/m2 daily day 1 , 2 , 8 , 9 , 15 , 16 follow 13-day rest period ( day 17 28 ) . Bendamustine = 50 mg/m2 day 1 , 8 every 28 day Dexamethasone = 20 mg day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 every 28 day . Level -1 Carfilzomib = 20 mg/m2 IV daily day 1 , 2 cycle 1 follow 27 mg/m2 day 8 , 9 , 15 , 16 cycle 1 , subsequent dose 27 mg/m2 daily day 1 , 2 , 8 , 9 , 15 , 16 , follow 13-day rest period ( day 17 28 ) . Bendamustine = 60 mg/m2 day 1 , 8 every 28 day Dexamethasone = 20 mg day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 every 28 day . Level 0 Carfilzomib = 20 mg/m2 IV daily day 1 , 2 cycle 1 follow 27 mg/m2 day 8 , 9 , 15 , 16 cycle 1 , subsequent dose 27 mg/m2 IV daily day 1 , 2 , 8 , 9 , 15 , 16 follow 13-day rest period ( day 17 28 ) . Bendamustine = 70 mg/m2 day 1 , 8 every 28 day Dexamethasone = 20 mg day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Level +1 Carfilzomib = 20 mg/m2 IV daily day 1 , 2 , cycle 1 follow 36 mg/m2 day 8 , 9 , 15 , 16 cycle 1 , subsequent dose 36 mg/m2 IV daily day 1 , 2 , 8 , 9 , 15 , 16 , follow 13-day rest period ( day 17 28 ) . Bendamustine = 70 mg/m2 day 1 , 8 every 28 day Dexamethasone = 20 mg day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Level +2 Carfilzomib = 20 mg/m2 IV daily day 1 , 2 , cycle 1 follow 45 mg/m2 day 8 , 9 , 15 , 16 cycle 1 , subsequent dose 45 mg/m2 IV daily day 1 , 2 , 8 , 9 , 15 , 16 , follow 13-day rest period ( day 17 28 ) . Bendamustine = 70 mg/m2 day 1 , 8 every 28 day Dexamethasone = 20 mg day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Patients observe first two cycle therapy assessment side effect observation DLTs . Dose escalation proceed follow : - 3 patient enter dose level 0 . - If none 3 experience DLT , dose escalation continue . - If one three patient experience DLT , three additional patient add cohort ( max 6 ) . - If two three patient experience DLT give dose , MTD exceed MTD precede dose &lt; one 6 patient experienced DLT . If dose level zero tolerate , next level level -1 . - If patient experience DLT ( 1 6 ) dose escalation continue . - If 2 patient experience DLT ( 2 6 ) MTD exceed MTD previous dose &lt; 1 patient 6 experienced DLT . PHASE II In second part study , MTD association CBd ( absence MTD observe dos dose level 2 ) administer , dose level superior phase Ib , total 50 consecutive patient order assess response rate clinical efficacy . MAINTENANCE PERIOD At end 8 course , maintenance phase start . Patients receive : Carfilzomib = 27 mg/ m2 IV day 1 , 2 , 15 , 16 follow 13-day rest period ( day 17 28 ) . Dexamethasone = 20 mg day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Patients stop PD intolerance . STUDY ENDPOINTS Primary endpoint : All patient include Intent-to-Treat ( ITT ) analysis . DLTs define follow : - Any CTCAE grade ≥3 non-hematologic event except follow : 1 . Nausea vomit responds symptomatic therapy . - Grade 4 neutropenia last 7 day . - Grade 4 hematologic toxicity except neutropenia - Development febrile neutropenia define grade 3-4 neutropenia fever 38.5°C and/or infection require antibiotic antifungal treatment . Assessment DLT define adverse event perform completion second cycle ( phase Ib ) accord National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE version 4.0 ) . Efficacy assess consider VGPR follow propose regimen , accord criterion International Myeloma Working Group Secondary endpoint : - Determine ORR . - Determine PFS . - Determine time point best response . - Determine TTP . - Determine DFS . - Determine DOR . - Determine TTNT . - Determine OS . Determine whether tumor response survival might significantly change particular subgroup patient define prognostic factor ( β2-microglobulin , C-reactive protein ( CRP ) , cytogenetic abnormality previous treatment ) . STATISTICAL METHODS The sample size first part study ( Phase I ) base scenario group assume CBd dose level -1/+2 make minimum 3 patient maximum 6 patient . This bring total 18 patient , maximum number patient recruit . The sample size second part study ( Phase II ) estimate accord Two-stage Simon phase II design , early stopping rule , case efficacy result lower predefined uninteresting response rate . A VGPR rate 20 % ( p0 ) consider promising ( H0 ) 40 % ( p1 ) VGPR rate interesting ; probability type I ( α ) error set 0.05 type II ( β ) error 0.20 . In first stage , 13 patient accrue . If 3 less response observe stage I , trial stop futility . Otherwise , 30 additional patient accrue second stage : 12 few response observe end stage II , investigation warrant . With design , H0 would true , expect number enrol patient 43 probability early termination 74.7 % . Assuming 10-15 % patient lose follow-up , adequate sample size 50 patient . Therefore maximum total number patient recruit phase 68 . STUDY DURATION : Approximately 5 year TOTAL SAMPLE SIZE : Up 68 patient STUDY DRUG SUPPLIERS : Mundipharma International Onyx Pharmaceuticals</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient ≥ 18 year old . Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient either postmenopausal surgically sterilize commits continue abstinence heterosexual intercourse duration study willing use two method birth control , one highly effective method one additional effective method time , least 4 week start carfilzomib bendamustine therapy , carfilzomib bendamustine therapy least 4 week stop carfilzomib bendamustine therapy . Highly effective method hormonal contraceptive ( birth control pill , injection , implant ) , intrauterine device , tubal ligation partner 's vasectomy . Additional effective method condom , diaphragm , cervical cap . Women child bear potential must two negative pregnancy test ( sensitivity least 50 mIU/mL ) prior start carfilzomib bendamustine therapy . The first pregnancy test must perform 10 14 day second within 24 hour start carfilzomib bendamustine therapy . Pregnancy test first 4 week study therapy must perform weekly thereafter every 4 week menstrual cycle regular every 2 week menstrual cycle irregular . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) duration study 6 month stop study therapy . Patient relapse or/and refractory multiple myeloma failure two treatment regimen ( previous bortezomib allow ) . Patient measurable disease , define follow : quantifiable serum monoclonal protein ( Mprotein ) value ( generally , necessarily , ≥ 0.5 g/dL Mprotein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . For patient oligo nonsecretory MM , require measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) abnormal free light chain ratio ( n.v. : 0.261.65 ) . We anticipate less 10 % patient admit study oligo nonsecretory MM free light chain order maximize interpretation benefit result . Patient Karnofsky performance status ≥60 % . Patient life expectancy &gt; 6 month . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 , study drug administration ) : Platelet count ≥70 x 109/L ( ≥50 x 109 /L myeloma involvement bone marrow &gt; 50 % ) within 14 day prior drug administration ) . Absolute neutrophil count ( ANC ) ≥ 1 x 109/L without use growth factor . Corrected serum calcium ≤14 mg/dL ( 3.5 mmol/L ) . Alanine transaminase ( ALT ) : ≤ 3 x ULN . Total bilirubin : ≤ 2 x ULN . Calculated measured creatinine clearance ≥ 15 mL/min ( , alternative serum creatinine &lt; 2 mg/dL ) . LVEF ≥ 40 % . 2D transthoracic echocardiogram ( ECHO ) prefer method evaluation . Multigated Acquisition Scan ( MUGA ) acceptable ECHO available ( applicable Germany ) . Pregnant lactate female Patient active infectious hepatitis type B C HIV . Patients active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention . Peripheral neuropathy ( PN ) &gt; CTCAE grade 2 ≥ grade 2 painful PN ( difference exclusion patient Grade 2 painful PN ) . Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) Known history intolerability high dose dexamethasone Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . Subject pleural effusion require thoracentesis ascites require paracentesis within 14 day prior baseline ; Patient clinically significant illness would , investigator 's opinion , increase patient 's risk toxicity . Patient prior malignancy within last 5 year ( except basal squamous cell carcinoma skin , situ cancer cervix breast , localized prostate cancer Gleason score &lt; 7 stable PSA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>REFRACTORY OR RELAPSED</keyword>
	<keyword>CBD</keyword>
</DOC>